Inmune Bio Inc. earnings releases INMB

Annual Quarterly

Inmune Bio Inc. last reported quarterly results on Oct 30, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $0 and diluted EPS of -$0.24. It usually reports 30–38 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–38 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Oct 30, 2025 30 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0	-6 +46.5%	-0.24 +60.0%
Aug 7, 2025 38 days after quarter end	Q2 FY2025 ended Jun 30, 2025	0	-24 -151.0%	-1.05 -110.0%
May 8, 2025 38 days after quarter end	Q1 FY2025 ended Mar 31, 2025	0 +257.1%	-10 +11.7%	-0.43 +29.5%
Nov 1, 2024 32 days after quarter end	— ended Sep 30, 2024	—	—	—
Aug 2, 2024 33 days after quarter end	— ended Jun 30, 2024	—	—	—
May 13, 2024 43 days after quarter end	— ended Mar 31, 2024	—	—	—
Nov 1, 2023 32 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 8, 2023 39 days after quarter end	— ended Jun 30, 2023	—	—	—

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: INMB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: NV
Headquarters: Boca Raton, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1711754

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.